Canaccord Genuity Maintains Buy on Definium Therapeutics, Lowers Price Target to $58
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and lowers the price target from $60 to $58.
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and lowers the price target from $60 to $58.